We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


OriGene and Cytomyx Collaborate to Develop Biomarker Validation Technologies

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "OriGene and Cytomyx Collaborate to Develop Biomarker Validation Technologies "

First Name*
Last Name*
Email Address*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Read time:

OriGene Technologies Inc. has announced that they have entered into an agreement with Cytomyx Holdings, PLC to co-develop tools to profile gene expression and biomarker validation in a range of human cancers.

Under the terms of the agreement, Cytomyx will supply hundreds of characterized RNA samples from a wide range of major cancers from its extensive Biorepository.

OriGene will use these samples to develop generations of their existing Rapid-Scan Gene Expression Panel product line.

The Rapid-Scan panels will enable researchers to profile gene expression levels in these patient derived samples to determine linkages between gene expression and tumor occurrence and development.

Cytomyx also intends to develop complementary tissue microarrays (TMAs), which can be used to further investigate these linkages at the protein expression level using immunohistochemistry.

“The development of this new high-throughput analysis system will enable researchers to rapidly assess gene expression levels across a wide range of patients with different forms and stages of the major cancers,” said Mike Kerins, CEO of Cytomyx.

“As such we expect that it will become an important new resource in the effort to characterize tumors at the genetic level and may help in the development of precisely targeted new diagnostics and therapies in the future.”

“We are pleased to be working with OriGene who have established themselves as a leading developer of genetic research products.”

“In particular their access to the global market for research products will help to ensure the success of this important new product line.”

“Having a tool that demonstrates correlation of mRNA levels to detailed disease stages is critical for biomarker validation,” said Rich Hamer, PhD, VP Business Development at OriGene.

“OriGene's Rapid-Scan platform combined with the depth of Cytomyx' Biorepository greatly enhances the target screening and biomarker validation toolset needed by today's researchers.”